Abstract 1683P
Background
Myeloproliferative neoplasms (MPN) are chronic haematological malignancies including myelofibrosis (MF), polycythaemia vera (PV) and essential thrombocythemia (ET). People with MPN require proper education to confidently manage their health at home. If they develop high levels of self-care confidence, they might be more capable of performing self-care behaviours and improving their quality of life. This study aims to preliminary assess the self-care confidence of MPN patients and its association with their quality of life.
Methods
This is a descriptive cross-sectional study conducted by the Italian Association of MPN Patients (AIPAMM). Preliminary data from 9 haematology centres in Italy were analysed. During their outpatient visit, patients with MPN were given a paper-and-pencil questionnaire to measure self-care confidence using the Self-Care Confidence Scale, symptom burden using the MPN-SAF TSS, and quality of life using the EORTC QLQ-C30.
Results
The study included 292 adult patients with MPN (55% male; mean age = 60 years ± 14). They were diagnosed with MF (42%), ET (30%), or PV (28%). The most burdensome symptoms were fatigue, problems with concentration, abdominal discomfort, and inactivity. Participants rated their overall quality of life as 69.5 ± 22.8 (range 0-100). The mean level of self-care confidence was 77.4 ± 16.3 (range 0-100). We found that a higher level of self-care confidence is associated with lower symptom burden (r = -.24; p <. 001) and greater quality of life (r =. 30; p <. 001).
Conclusions
This study revealed that enhancing self-care confidence in MPN patients can decrease their symptom burden and improve their quality of life. Health professionals should educate and support people living with MPN in performing self-care behaviours to enhance their ability to manage their health at home and their level of confidence. In particular, patients should be empowered to utilize suitable strategies to address fatigue and problems with concentration.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1687P - Perceptions of genetic testing and lived experiences in women with locally advanced or metastatic ovarian cancer: A focus on BRCAm and BRCAwt patients
Presenter: María Jesús Rubio Pérez
Session: Poster session 11
1688P - Psychosocial distress and spirituality among elderly patients with cancer in Nigeria
Presenter: Zainab Ogunjimi
Session: Poster session 11
1689TiP - The social stigma of smokers and patients with lung cancer: Detection of phoenomenon and testing of EMDR (eye movement desensitization and reprocessing) intervention
Presenter: Domenico Galetta
Session: Poster session 11
1692P - A phase Ib/IIa trial to evaluate the safety and efficacy of PM8002/ BNT327, a bispecific antibody targeting PD-L1 and VEGF-A, as a monotherapy in patients with advanced renal cell carcinoma
Presenter: Xinan Sheng
Session: Poster session 11
1693P - CaboPoint: Final results from a phase II study of cabozantinib after checkpoint inhibitor (CPI) combinations in patients with advanced renal cell carcinoma (aRCC)
Presenter: Laurence Albiges
Session: Poster session 11
1695P - Phase I LITESPARK-018: Dose escalation study of belzutifan in advanced pretreated clear cell renal cell carcinoma (ccRCC)
Presenter: Ulka Vaishampayan
Session: Poster session 11
1696P - A phase I/ II trial of pazopanib (Paz) alternating (alt) with bevacizumab (Bev) in treatment-naïve metastatic clear cell renal cell carcinoma (mccRCC) patients (pts): Phase II results
Presenter: Saby George
Session: Poster session 11
1697P - Phase II randomized double-blind trial of axitinib (Axi) +/- PF 04518600, an OX40 antibody (PFOX) after PD1/PDL1 antibody (IO) therapy (Tx) in metastatic renal cell carcinoma (mRCC): Final analysis
Presenter: Sarmad Sadeghi
Session: Poster session 11
1698P - Avelumab + axitinib (Ave + Axi) vs sunitinib (Sun) in advanced renal cell carcinoma (aRCC): Final analysis of patient (pt)-reported outcomes (PROs) and quality-adjusted time without symptoms or toxicity (Q-TWiST)
Presenter: Balaji Venugopal
Session: Poster session 11